Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage
biopharmaceutical company focused on addressing the large unmet
need in transthyretin (TTR) amyloidosis (ATTR), today
announced the appointment of William Lis, to Eidos’ Board of
Directors, effective December 4, 2018. Mr. Lis has more than
25 years of experience in the biopharmaceutical industry, including
serving as chief executive officer of Portola Pharmaceuticals, Inc.
“Bill is an accomplished biopharmaceutical executive with a
proven track record in building and leading organizations, and has
significant expertise in successfully developing new therapies in
the field of cardiology,” said Neil Kumar, PhD., chief executive
officer of Eidos. “We are pleased to welcome Bill to our Board of
Directors. Bill’s extensive experience will serve us well as we
continue to advance the clinical development of AG10, a potentially
disease-modifying therapy for the treatment of ATTR.”
“With the Phase 3 study of AG10 expected to start in 2019, this
is an important time for Eidos,” said Mr. Lis. “I look forward to
leveraging my experience in building biopharmaceutical
organizations and developing novel therapies to help Eidos achieve
its mission of developing a potentially best-in-class treatment for
ATTR patients.”
William Lis has more than 25 years of biopharmaceutical
experience. He served as Chief Executive Officer and a director of
Portola Pharmaceuticals, Inc. from 2010 until 2018 after serving as
Chief Operating Officer and Chief Business Officer in 2009 and
2008, respectively. Under his leadership, Portola successfully grew
from a discovery stage company to a fully integrated R&D and
commercial organization, and independently advanced: Andexxa® and
Bevyxxa®, which received FDA Breakthrough and Fast Track
designation, respectively, from discovery and early stage
development through commercial launch, and cerdulatinib, a novel
immunology and oncology compound, from discovery through Phase 2
clinical development. He led private and public financings
including an initial public offering in 2013; multiple corporate
partnerships; academic clinical development collaborations; and
milestones that resulted in the growth of the company’s valuation
from $250 million to $2.7 billion during his tenure. Prior to
Portola, Mr. Lis held executive and management positions at Scios,
Inc. (a Johnson & Johnson company) from 2003 to 2008 where he
last served as Vice President of Commercial Operations and Business
Development, having led efforts for the in-licensing, and then the
strategic development and pre-commercial launch for Xarelto®. He
also held positions of increasing responsibility at Millennium
Pharmaceuticals, Inc. (previously COR Therapeutics, Inc.) from 1998
to 2003 in commercial and medical affairs for INTEGRILIN® and early
stage compounds, Earlier in his career, he was involved in the U.S.
commercial launch of several products with multiple pharmaceutical
companies, including Lovenox® and Rilutek® while at Rhone-Poulenc
Rorer. Mr. Lis serves as independent director for Zai Lab Limited
(ZLAB, Nasdaq) and served as a member of the Biotechnology
Innovation Organization (BIO) Board of Directors for the Emerging
Companies Section in 2015 and 2016. Mr. Lis holds a B.S. from the
University of Maryland.
Additionally, Eidos also announced that Hoyoung Huh, MD, PhD,
who has served as a member of Eidos’s Board of Directors since
March 2016, has stepped down from his role as a director of Eidos,
effective as of December 4, 2018. Dr. Huh will continue as a
consultant to Eidos through his leadership at BridgeBio Pharma LLC,
the parent company and majority shareholder of Eidos.
“We are grateful for Hoyoung’s service to Eidos,” stated Dr.
Kumar. “His leadership and guidance have been instrumental in the
progress we have achieved at Eidos.”
About AG10
AG10 is an investigational, orally-administered small molecule
designed to potently stabilize tetrameric transthyretin, or TTR,
thereby halting at its outset the series of molecular events that
give rise to amyloidosis, or ATTR. In a Phase 2 clinical trial in
ATTR-CM patients, AG10 was well tolerated, demonstrated >90% TTR
average stabilization at day 28, and increased serum TTR
concentrations, a prognostic indicator of survival in ATTR-CM in a
dose-dependent manner. AG10 is currently being studied in an
open-label extension of a Phase 2 clinical trial in patients with
ATTR cardiomyopathy. Subject to discussions with regulatory
agencies, Eidos plans to initiate Phase 3 pivotal studies of AG10
in the first half of 2019.
AG10 was designed to mimic a naturally-occurring variant of the
TTR gene (T119M) that is considered a “rescue mutation” because it
has been shown to prevent ATTR in individuals carrying pathogenic,
or disease-causing, mutations in the TTR gene. To our knowledge,
AG10 is the only TTR stabilizer in development that has been
observed to mimic the “super-stabilizing” properties of this rescue
mutation.
About transthyretin amyloidosis (ATTR)
ATTR represents a significant unmet need of a comparatively
large patient population in the context of rare genetic diseases
with an inadequate current standard of care. There are three
distinct diseases that comprise the ATTR family: wild-type ATTR
cardiomyopathy (ATTRwt-CM), mutant ATTR cardiomyopathy (ATTRm-CM),
and ATTR polyneuropathy (ATTR-PN). The worldwide prevalence of each
disease is approximately 400,000 patients, 40,000 patients and
10,000 patients, respectively.
All three forms of ATTR are progressive and fatal. For patients
with ATTRwt-CM and ATTRm-CM, symptoms usually manifest later in
life (age 50+), with median survival of three to five years from
diagnosis. ATTR-PN either presents in a patient’s early 30s or
later (age 50+), and results in a median life expectancy of five to
ten years from diagnosis. Progression of all forms of ATTR causes
significant morbidity, impacts productivity and quality of life,
and creates a significant economic burden due to the costs
associated with progressively greater patient needs for supportive
care.
About Eidos Therapeutics
Eidos Therapeutics is a clinical stage biopharmaceutical company
focused on addressing the large and growing unmet need in diseases
caused by transthyretin (TTR) amyloidosis (ATTR). For more
information, please visit www.eidostx.com.
Forward-Looking Statements
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act. All statements other than
statements of historical facts, including the statements about the
potential therapeutic and clinical benefits of AG10, its potential
to become a best-in-class treatment for ATTR-CM, future clinical
milestones of AG10, including the initiation of Phase 3 pivotal
studies for AG10, the timing of these events, the indications we
intend to pursue and our possible clinical or other business
strategies, are forward-looking statements. Forward-looking
statements can be identified by terms such as “believes,”
“expects,” “plans,” “potential,” “would” or similar expressions and
the negative of those terms. These forward-looking statements are
based on our management’s current beliefs and assumptions about
future events and on information currently available to
management.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. These risks include, but are not
limited to, risks and uncertainties related to: our limited
operating history and historical losses, our liquidity to fund the
development of AG10 through current and future milestones, our
ability to raise additional funding to complete the development of
AG10, our dependence on the success of AG10, results from our
clinical trials and pre-clinical studies and those of
third parties working in the same area as our product candidate,
our ability to advance AG10 in clinical development in accordance
with our plans, and our dependence on third parties in connection
with our manufacturing, clinical trials
and pre-clinical studies. Additional risks and
uncertainties that could affect our future results are included in
the section titled “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” in our
Quarterly Report on Form 10-Q for the quarter ended September 30,
2018, which is available on the SEC’s website
at www.sec.gov and our website at eidostx.com. Additional
information on potential risks will be made available in other
filings that we make from time to time with the SEC. In addition,
any forward-looking statements contained in this press release are
based on assumptions that we believe to be reasonable as of this
date. Except as required by law, we assume no obligation to update
these forward-looking statements, or to update the reasons if
actual results differ materially from those anticipated in the
forward-looking statements.
Media Contact:Carolyn Hawley Canale
Communications619-849-5382Carolyn@canalecomm.com
Investor Contact:Alex GrayBurns
McClellan212-213-0006agray@burnsmc.com
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From Apr 2024 to May 2024
Eidos Therapeutics (NASDAQ:EIDX)
Historical Stock Chart
From May 2023 to May 2024